On May 6, 2022 Affimed N.V. (Nasdaq: AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) has informed the Company’s collaborator that it has removed the previously announced oral presentation on AFM13-104, the investigator sponsored trial that evaluates AFM13 pre-complexed with NK cells in patients with relapsed/refractory CD30-positive lymphomas, from the upcoming conference program (Press release, Affimed, MAY 6, 2022, View Source [SID1234613847]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Per ASCO (Free ASCO Whitepaper), the decision was solely based on its embargo policy which restricts data in submitted abstracts from presentation at any prior conference or forum. Data from AFM13-104 was recently presented in an oral session at the Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) on April 10, 2022, in New Orleans, Louisiana.

The removal of the presentation is not related to the status or results of the ongoing trial. Affimed respects ASCO (Free ASCO Whitepaper)’s decision and is working with The University of Texas MD Anderson Cancer Center on plans to submit additional data on AFM13-104 to a future scientific forum.